160 related articles for article (PubMed ID: 24588516)
1. Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice.
Chu C; Abbara C; Tandia M; Polrot M; Gonin P; Farinotti R; Bonhomme-Faivre L
Fundam Clin Pharmacol; 2014 Dec; 28(6):652-60. PubMed ID: 24588516
[TBL] [Abstract][Full Text] [Related]
2. In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab.
Ettlinger DE; Mitterhauser M; Wadsak W; Ostermann E; Farkouh A; Schueller J; Czejka M
Anticancer Res; 2006; 26(2B):1337-41. PubMed ID: 16619542
[TBL] [Abstract][Full Text] [Related]
3. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Stewart CF; Leggas M; Schuetz JD; Panetta JC; Cheshire PJ; Peterson J; Daw N; Jenkins JJ; Gilbertson R; Germain GS; Harwood FC; Houghton PJ
Cancer Res; 2004 Oct; 64(20):7491-9. PubMed ID: 15492275
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.
Doi T; Muro K; Yoshino T; Fuse N; Ura T; Takahari D; Feng HP; Shimamoto T; Noguchi K; Ohtsu A
Cancer Chemother Pharmacol; 2013 Sep; 72(3):643-52. PubMed ID: 23921573
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.
Czejka M; Gruenberger B; Kiss A; Farkouh A; Schueller J
Anticancer Res; 2010 Jun; 30(6):2355-60. PubMed ID: 20651393
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
Delbaldo C; Pierga JY; Dieras V; Faivre S; Laurence V; Vedovato JC; Bonnay M; Mueser M; Nolting A; Kovar A; Raymond E
Eur J Cancer; 2005 Aug; 41(12):1739-45. PubMed ID: 16051481
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
12. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
[TBL] [Abstract][Full Text] [Related]
14. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
16. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
[TBL] [Abstract][Full Text] [Related]
17. Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.
Prewett M; Bassi R; Paz K; Amatulli M; Deevi D; Li H; Wang S; Witte L; Samakoglu S; Tonra JR
Anticancer Res; 2011 Jun; 31(6):2149-60. PubMed ID: 21737635
[TBL] [Abstract][Full Text] [Related]
18. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
Middleton G; Brown S; Lowe C; Maughan T; Gwyther S; Oliver A; Richman S; Blake D; Napp V; Marshall H; Wadsley J; Maisey N; Chau I; Hill M; Gollins S; Myint S; Slater S; Wagstaff J; Bridgewater J; Seymour M
Eur J Cancer; 2013 Nov; 49(16):3507-16. PubMed ID: 23953030
[TBL] [Abstract][Full Text] [Related]
19. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
